Antares Pharma, Inc. (ATRS)

R&D Expense Growth

28.67%

Quarterly · Period ending:

ATRS logo

ATRS R&D Expense Growth

Latest reported28.67%
ATRS Quarterly R&D Growth (QoQ) (0.00% → 28.67%)
High-resolution chart · PNG

ATRS r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Antares Pharma, Inc. R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
28.6742%
-0.7902%
-3.064%
53.2955%
13.8913%
-3.6175%
-0.4965%
-18.9198%
3.5069%
0.5938%
14.7955%
4.4826%
36.6342%
-51.62%
-1.0685%
9.9398%
-8.0819%
9.8031%
4.1173%
2.368%
-44.6142%
-6.4817%
50.925%
-30.0992%
0.0986%
9.7246%
12.5561%
4.3571%
-23.6582%
29.5474%
12.2696%
-13.0288%
51.6052%
-32.9508%
-2.6955%
41.9349%
-42.9557%
45.1395%
57.1008%
-13.7072%
82.741%
10.1621%
-26.569%
11.2611%
-18.3003%
-8.2108%
4.0095%
7.5252%
7.213%
-2.9639%
14.8748%
-20.9108%
12.8346%
-9.1731%
20.2127%
-8.903%
44.0587%
-17.3848%
8.5743%
84.7579%
-26.8253%
35.198%
-13.2268%
11.4202%
96.7137%
-52.5339%
-14.8862%
12.1459%
-30.9508%
59.1246%
45.5814%
-9.034%
-53.4264%
113.9927%
-3.0742%
-3.8383%
-43.5233%
49.9713%
3.7127%
11.2927%
-50.4388%
115.0771%
-16.7431%
52.0794%
51.5257%
18.0568%
4.8411%
5.4669%
-47.1072%
-13.7035%
20%
-28.5714%
-56.7061%
130.9794%
16.6667%
0%
-10.9547%
12.3023%
-14.2857%
16.6667%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.